

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C07K 7/56, A61K 37/02	A1	(11) International Publication Number: WO 94/21677 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/US94/02580 (22) International Filing Date: 10 March 1994 (10.03.94) (30) Priority Data: 032,847 16 March 1993 (16.03.93) US (60) Parent Application or Grant (63) Related by Continuation US 032,847 (CON) Filed on 16 March 1993 (16.03.93) (71) Applicant (for all designated States except US): MERCK & CO. INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BALKOVEC, James, M. [US/US]; 210 Clinton Avenue, North Plainfield, NJ 07063 (US). BOUFFARD, Frances, Aileen [US/US]; 1521 Cooper Road, Scotch Plains, NJ 07076 (US). BLACK, Regina, M. [US/US]; 6 Roselle Avenue, Cranford, NJ 07016 (US). (74) Agent: KORSEN, Elliott; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: BB, BG, BR, BY, CN, CZ, FI, HU, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: AZA CYCLOHEXAPEPTIDE COMPOUNDS (57) Abstract Certain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


- 1 -

TITLE OF THE INVENTION

AZA CYCLOHEXAPEPTIDE COMPOUNDS

The present invention is directed to certain aza
cyclohexapeptide compounds and to processes for their preparation.

The aza cyclohexapeptide compounds of the present
invention, Compound I (Seq ID Nos. 1-15) are characterized in having a
nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-
hydroxy ornithine component (hereinafter "C-5-orn") and may be
represented by the formula



(I)

wherein

R_1 is H or OH

R_2 is H, CH₃ or OH

R_3 is H, CH₃, CH₂CN, CH₂CH₂NH₂ or CH₂CONH₂

R^I is C₉-C₂₁ alkyl, C₉-C₂₁ alkenyl, C₁-C₁₀
alkoxyphenyl or C₁-C₁₀ alkoxyphenyl

R^{II} is H, C₁-C₄ alkyl, C₃-C₄ alkenyl, (CH₂)₂-4OH,
(CH₂)₂-4NR^{IV}R^V, CO(CH₂)₁₋₄NH₂

- 2 -

R^{III} is H, C₁-C₄ alkyl, C₃-C₄ alkenyl, (CH₂)₂-4OH,
(CH₂)₂-4NR^{IV}R^V, or

R^{II} and
R^{III} taken together are -(CH₂)₄-, -(CH₂)₅-,
-(CH₂)₂O(CH₂)₂- or -(CH₂)₂-NH-(CH₂)₂-

R^{IV} is H or C₁-C₄ alkyl

R^V is H or C₁-C₄ alkyl; and

acid addition salts thereof.

Where the expression "alkyl", "alkenyl" or "alkoxy" is employed, it is intended to include branched as well as straight chain radicals.

The compounds of the present invention are generally obtained as mixtures of stereoisomeric forms in which one form usually predominates. Conditions may be adjusted by means within the normal skill of the skilled artisan to obtain predominantly the desired isomer. The compounds with preferred stereoisomeric form designated herein as the "normal" form may be seen in the working examples with the dashed lines below the plane at the "C-5-orn" position. The designation "epi" has been employed for those compounds in which the group at the "C-5-orn" position is above the plane.

Pharmaceutically acceptable salts suitable as acid addition salts are those from acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, maleic, citric, acetic, tartaric, succinic, oxalic, malic, glutamic and the like, and include other acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977).

Representative nuclei for the aza derivatives of the present invention (Compound I) and the sequence ID for these compounds may be seen in the following table. Since the peptide nuclei would be the same irrespective of substituents R^I, R^{II} or R^{III}, and since the sequence identification number is assigned for the nuclear variations, the amines and salts have the same sequence ID's.


- 3 -

	Aza Compound	R _I	R _{II}	R _{III}	SEQ ID NO
5	I-1	H	H	CH ₂ CONH ₂	1
	I-2	H	H	CH ₂ CN	2
	I-3	H	H	CH ₂ CH ₂ NH ₂	3
	I-4	OH	H	CH ₂ CONH ₂	4
	I-5	OH	H	CH ₂ CN	5
10	I-6	OH	H	CH ₂ CH ₂ NH ₂	6
	I-7	OH	CH ₃	CH ₂ CONH ₂	7
	I-8	OH	CH ₃	CH ₂ CN	8
	I-9	OH	CH ₃	CH ₂ CH ₂ NH ₂	9
	I-10	OH	CH ₃	CH ₃	10
15	I-11	OH	CH ₃	H	11
	I-12	OH	OH	CH ₂ CONH ₂	12
	I-13	OH	OH	CH ₂ CN	13
	I-14	OH	OH	CH ₂ CH ₂ NH ₂	14
20	I-15	H	CH ₃	CH ₃	15

One of the compounds which is particularly outstanding for the control of mycotic infections is a compound identifiable as Compound I-6 wherein R^{II} is H, R^{III} is CH₂CH₂NH₂ and R^I is 9,11-dimethyltridecyl (DMTD), and which may be referred to specifically as Compound I-6-1 (Seq ID No. 6).

30

- 4 -



In the above designation I-6-1 refers to the first compound in which the nuclear arrangement is I-6. Since in all the compounds of the present invention the substituent at the "C-5-orn" is nitrogen, the substituents on said nitrogen may vary and still all compounds which have the same R₁, R₂ and R₃ would be Seq ID No. 6.


The compounds are soluble in lower alcohols, and polar aprotic solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and pyridine. They are insoluble in solvents such as diethyl ether and acetonitrile.

The compounds of the present invention are useful as an antibiotic, especially as an antifungal agent or as an antiprotozoal agent. As antifungal agents they are useful for the control of both filamentous fungi and yeasts. They are especially adaptable to be employed for the treatment of mycotic infections in mammals, especially those caused by Candida species such as C. albicans, C. tropicalis and C. pseudotropicalis, Cryptococcus species such as C. neoformans and Aspergillus species such as A. fumigatus, A. flavus, A. niger. They are also useful for the treatment and/or prevention of Pneumocystis carinii

- 5 -

pneumonia to which immune-compromised patients are especially susceptible as hereinafter described.

The compounds of the present invention may be prepared from cyclopeptides having the formula



(Seq ID Nos. 1-15)

by a series of reactions in which the oxygen atom at the "C-5-orn" (which also may be referred to as the hemiaminal position) is ultimately replaced by nitrogen. The starting materials may be natural products or modified natural products as subsequently described. When R₁ is hydrogen instead of hydroxyl, the product aza compounds may be prepared by an alternate series of reactions. The method applicable for the preparation of compounds in which R₁ may be either H or OH is first described.

The sequence IDs of the starting materials are seen in the following table:

- 6 -



	Compound	R ₁	R ₂	R ₃	Starting Material SEQ ID NO.
5	A-1	H	H	CH ₂ CONH ₂	16
	A-2	H	H	CH ₂ CN	17
	A-3	H	H	CH ₂ CH ₂ NH ₂	18
	A-4	OH	H	CH ₂ CONH ₂	19
	A-5	OH	H	CH ₂ CN	20
10	A-6	OH	H	CH ₂ CH ₂ NH ₂	21
	A-7	OH	CH ₃	CH ₂ CONH ₂	22
	A-8	OH	CH ₃	CH ₂ CN	23
	A-9	OH	CH ₃	CH ₂ CH ₂ NH ₂	24
	A-10	OH	CH ₃	CH ₃	25
15	A-11	OH	CH ₃	H	26
	A-12	OH	OH	CH ₂ CONH ₂	27
	A-13	OH	OH	CH ₂ CN	28
	A-14	OH	OH	CH ₂ CH ₂ NH ₂	29
20	A-15	H	CH ₃	CH ₃	30

Compounds A-4 and A-7 have been identified in the literature (J. Antibiotics 45, 1855-60 Dec. 1992) as pneumocandin B₀ and pneumocandin A₀ when R^I = DMTD.

When in Compound A-1, R₁ and R₂ are represented by any of the possible variables and R₃ is -H, CH₃ or -CH₂CONH₂ (Seq ID Nos. 16, 19, 22, 25-27 and 30), they may be directly employed in the first method. When R₃ is -CH₂CN or -CH₂CH₂NH₂, the group -CH₂CONH₂ may be first converted to -CH₂CN or -CH₂CH₂NH₂ as subsequently disclosed and all the modified compounds (Seq ID Nos. 17-18, 20-21, 23-24, 28-29) used in the first method, or alternatively, a compound in which R₃ is -CH₂CONH₂ may be employed to produce a compound with N at the hemiaminal position, and the -CH₂CONH₂ of the resulting product then converted to -CH₂CN or -CH₂CH₂NH₂.

- 7 -


First, when R₁, R₂ and R₃ of the starting material are the same as that in the product, the following sequence may be employed.



* The position is the "C-5-orn" or the hemiaminal position.

30

- 8 -



In Step A, the starting material Compound A (Seq ID Nos. 16-30), alkylthiol or arylthiol and acid are caused to react in an aprotic solvent under anhydrous conditions for time sufficient for reaction to take place with the formation of Compound B (Seq ID Nos. 31-45), seen in the following table. Aminoethylthiol has been found to be useful for this step.

- 9 -

	Compound	R ₁	R ₂	R ₃	Sulfur Intermediate SEQ ID
5	B-1	H	H	CH ₂ CONH ₂	31
	B-2	H	H	CH ₂ CN	32
	B-3	H	H	CH ₂ CH ₂ NH ₂	33
	B-4	OH	H	CH ₂ CONH ₂	34
	B-5	OH	H	CH ₂ CN	35
10	B-6	OH	H	CH ₂ CH ₂ NH ₂	36
	B-7	OH	CH ₃	CH ₂ CONH ₂	37
	B-8	OH	CH ₃	CH ₂ CN	38
	B-9	OH	CH ₃	CH ₂ CH ₂ NH ₂	39
	B-10	OH	CH ₃	CH ₃	40
15	B-11	OH	CH ₃	H	41
	B-12	OH	OH	CH ₂ CONH ₂	42
	B-13	OH	OH	CH ₂ CN	43
	B-14	OH	OH	CH ₂ CH ₂ NH ₂	44
20	B-15	H	CH ₃	CH ₃	45

For Step A, suitable acids include strong organic acid and mineral acids. Examples of strong organic acids are camphorsulfonic acid, p-toluenesulfonic acid and methanesulfonic acid. Mineral acids include hydrochloric acid and hydrobromic acid. Camphorsulfonic acid is preferred.

Suitable solvents include DMF, DMSO, 1-methyl-2-pyrrolidinone and hexamethyl phosphoric triamide (HMPA). DMF or DMSO is preferred.

The reaction is generally carried out at ambient temperature for from 1 to about 10 days.

In carrying out the reaction, the cyclohexapeptide compound, the thiol compound and acid are stirred together in a suitable solvent until the reaction is substantially complete. The reaction mixture then is diluted with water and flash chromatographed on

- 10 -

reverse phase resins using 10 to 40 percent acetonitrile/water (containing 0.1% trifluoroacetic acid) as eluant. Trifluoroacetic acid may hereinafter be designated "TFA". The fractions containing the desired product may be concentrated and lyophilized and the lyophilized material purified by preparative high performance liquid chromatography (HPLC).

Appropriate columns for HPLC are commercially available columns sold under trade mark names or trade names such as "ZORBAX" (DuPont), "DeltaPak" (Waters), Bio-Rad (Bio-Rad), "LICHROPREP" RP18 (E. Merck). The specific columns are identified in the working examples.

In Step B, Compound C (Seq ID Nos. 31-45), a sulfone is obtained by the oxidation of Compound B. Suitable oxidizing agents or oxidants include "OXONE," ($\text{KHSO}_5 \cdot \text{KHSO}_4 \cdot \text{K}_2\text{SO}_4$ 2:1:1, Aldrich Chemicals) metachloroperoxybenzoic acid, and peroxyacetic acid. The sequence ID of Compound C is the same as that of Compound B since the atom attached to the hemiaminal carbon is still sulfur. Thus, the sequence IDs of the sulfones are as follows:

- 11 -

	Compound	R ₁	R ₂	R ₃	Sulfone SEQ ID
5	C-1	H	H	CH ₂ CONH ₂	31
	C-2	H	H	CH ₂ CN	32
	C-3	H	H	CH ₂ CH ₂ NH ₂	33
	C-4	OH	H	CH ₂ CONH ₂	34
	C-5	OH	H	CH ₂ CN	35
10	C-6	OH	H	CH ₂ CH ₂ NH ₂	36
	C-7	OH	CH ₃	CH ₂ CONH ₂	37
	C-8	OH	CH ₃	CH ₂ CN	38
	C-9	OH	CH ₃	CH ₂ CH ₂ NH ₂	39
	C-10	OH	CH ₃	CH ₃	40
15	C-11	OH	CH ₃	H	41
	C-12	OH	OH	CH ₂ CONH ₂	42
	C-13	OH	OH	CH ₂ CN	43
	C-14	OH	OH	CH ₂ CH ₂ NH ₂	44
	C-15	H	CH ₃	CH ₃	45

20

The oxidation of the thioether (Compound B) to the sulfone (Compound C) is carried out with about two molar amounts of the oxidant. When one molar amount of oxidant is employed, the product is a sulfoxide which may then be converted to the sulfone. The sulfoxides may be employed as an intermediate in the formation the aza compounds but the sulfone is preferred. A slight excess over the two molar amount of the oxidizing agent is employed.

25

The reaction is carried out in an aqueous medium, preferably a mixture of acetonitrile and water. About equal amounts are preferred although a range of 1:9 to 9:1 may be employed.

30

In carrying out the reaction, the oxidant is added to a solution of Compound B (Seq ID Nos. 31-45) in 1:1 acetonitrile/water and the mixture allowed to stand at ambient temperature for time sufficient to complete the reaction to obtain Compound C generally from about 30 minutes to one hour.

- 12 -

After completion of the reaction, the compound is recovered from the reaction mixture by diluting with water and chromatographing. Reverse phase (C18) flash column chromatography is suitable in this purification step. The preferred eluting agent is 30-45 percent acetonitrile/water (0.1% TFA) in 5 percent step gradients. The appropriate fractions are lyophilized to recover the desired sulfone intermediate, Compound C (Seq ID Nos. 31-45). The intermediate tends to be labile, thus the isolation should be carried out as rapidly as possible.

Compound C may be converted to a compound having a nitrogen directly attached to the "C-5-orn". As seen in the flow diagram, reaction of Compound C with an alkali metal azide produces an azide at that position (Compound D) while reaction with an amine compound (ammonia or amine) produces an amino group at the "C-5-orn" position, (Compound I). Compound D is an important intermediate for most of the compounds of the present invention. Although Compound D has nitrogen at "C-5-orn", since it is not a product, separate sequence ID Nos. are assigned for Compound D. Sequence ID Nos. for Compound D are found in the following table.

- 13 -

	Compound	R ₁	R ₂	R ₃	Azide SEQ ID
5	D-1	H	H	CH ₂ CONH ₂	46
	D-2	H	H	CH ₂ CN	47
	D-3	H	H	CH ₂ CH ₂ NH ₂	48
	D-4	OH	H	CH ₂ CONH ₂	49
	D-5	OH	H	CH ₂ CN	50
10	D-6	OH	H	CH ₂ CH ₂ NH ₂	51
	D-7	OH	CH ₃	CH ₂ CONH ₂	52
	D-8	OH	CH ₃	CH ₂ CN	53
	D-9	OH	CH ₃	CH ₂ CH ₂ NH ₂	54
	D-10	OH	CH ₃	CH ₃	55
15	D-11	OH	CH ₃	H	56
	D-12	OH	OH	CH ₂ CONH ₂	57
	D-13	OH	OH	CH ₂ CN	58
	D-14	OH	OH	CH ₂ CH ₂ NH ₂	59
	D-15	H	CH ₃	CH ₃	60

20

The azide may be obtained by adding alkali metal azide while stirring at ambient temperature to a solution of the sulfone (Compound C; Seq. ID Nos. 31-45) in an aprotic solvent for time sufficient to complete the reaction with the formation of the azide as determined by HPLC analysis. The reaction mixture then may be diluted with aqueous acid such as trifluoroacetic acid and then chromatographed to separate the desired azide (Compound D) from the reaction mixture. Reverse-phase (C18) flash column chromatography using 10-25 percent acetonitrile/water (0.1% TFA) in 5 percent step gradients is suitable for this procedure.

30

The azide (Compound D) may then be reduced to a compound having a free amino group which is among the products (Compound I, Seq ID Nos. 1-15) of the present invention.

The reduction may be carried out by mixing the azide compound (Compound I) with Pd/C in a solvent such as glacial acetic

- 14 -

acid and hydrogenating under balloon pressure for 10 to 20 hours. The product then may be recovered by first removing the catalyst by filtration and the filtrate lyophilized to obtain the amine compound (Seq ID 1-15) in which the amine is a primary amine.

5 The amine thus obtained may be converted into a substituted amine as subsequently described.

Compound I in which $-NR^{II}R^{III}$ is represented by $-NHCH_2CH_2NH_2$ or generically by $-NH(CH_2)_2-4NR^{IV}R^V$ may be prepared from the sulfone by a method in which a diamine $H_2N(CH_2)_2-4NR^{IV}R^V$ is caused to react with the sulfone (Compound C, Seq ID Nos. 31-45).


10 The reaction is carried out in an aprotic solvent such as those previously named and at ambient temperature. About tenfold molar excess of the amine compound is employed. The reaction may be carried out over one to several hours.

15 In carrying out the reaction, the appropriate amine is added to a solution of the sulfone in anhydrous aprotic solvent and the reaction mixture stirred at ambient temperature to obtain Compound I (Seq ID Nos. 1-15) in which the substituent at "C-5-om" is $-NR^{II}R^{III}$. The desired compound may then be recovered by diluting with aqueous trifluoroacetic acid and then chromatographing. Reverse phase (C18) flash column chromatography eluting with 10 to 25% acetonitrile/water (0.1% TFA) in 5 percent step gradients is suitable. The appropriate fractions may be lyophilized to recover the product as a trifluoroacetate salt.

20 The trifluoroacetate salt may be converted by dissolving the salt in water and passing through a Bio-Rad AG2-X8(Cl-) polyprep column and recovering the product as the hydrochloride salt.

25 When R_1 in formula (I) is hydrogen, Compound I' (Seq ID Nos. 1-3, 15), the nitrogen may be introduced directly into the hemiaminal position by a reaction to form the azide, which then is reduced to an amine which optionally may be alkylated or acylated to obtain the ultimate product. The reaction is seen by the following flow diagram.

- 15 -



20 Although R_1 is hydrogen in some natural product cyclohexapeptides, R_1 is more commonly hydroxyl. Thus, for a number of the compounds, Compound A' in the flow diagram is prepared as a first step from the corresponding compound in which R_1 is OH.

25 The preparation of the reduced compound may be carried out by stirring the appropriate hydroxy compound in LiClO_4 -diethyl ether at room temperature, adding trifluoroacetic acid, followed by triethylsilane and subjecting the mixture to rapid stirring for from 4 to 10 hours or until the starting hydroxy compound is no longer detectable by analytical HPLC. The reaction mixture is then poured into distilled water to obtain the reduced product as precipitate which then is recovered by conventional procedures. The reduced product thus obtained may be used with or without purification in the preparation of the azide.

30 Products in which R_1 is H, may be obtained by adding the modified cyclohexapeptide to a preformed solution of HN_3 . HN_3 may

- 16 -

be prepared from sodium azide and trifluoroacetic acid. The reaction is allowed to take place at room temperature to obtain the azide product which may be recovered by conventional procedures and purified by HPLC.

5 The purified azide compound may be reduced to the amine compound by hydrogenating with palladium/carbon in a manner similar to that previously described.

10 The amines, prepared as above and having a primary amino group $-NH_2$ described, may then be alkylated by conventional means to obtain a substituted amino group. Briefly, alkylation may be carried out by causing an appropriately substituted alkyl halide to react with the amine (Compound I, $NR^{II}R^{III}=NH_2$; Sequence ID Nos 1-15) in an aprotic solvent in the presence of a base to obtain the monosubstituted amine (Compound I, $NR^{II}R^{III}=NHR^{II}$ wherein R^{II} is C1-C4 alkyl, C3-C4 alkenyl, $(CH_2)_2-4OH$, and $(CH_2)_2-4NR^{IV}R^V$). The latter may be recovered from the reaction mixture by conventional procedures.


15 The amines, prepared as above described and having a primary amino group $-NH_2$, may be acylated by conventional means to obtain an acylated amino group. The acyl group contemplated is $CO(CH_2)_1-4NH_2$. Since this is a primary amino group, the amino of the acylating acid is protected such as with a benzyloxycarbonyl group before the acylation is carried out. An activated ester such as the pentafluorophenyl ester is preferably used. The acylation may be carried out in an aprotic solvent in the presence of base such as diisopropylethylamine at ambient temperature for from one to several hours to obtain the acylation product. The product may be recovered by diluting the reaction mixture with methanol and purifying by HPLC. The protecting group may be removed by conventional hydrogenolysis. (Compound I, $-NR^{II}R^{III}=-NHCO(CH_2)_1-4NH_2$).

20 The amine compounds in which the amino group at the hemiaminal position is totally substituted, i.e. when neither R^{II} nor R^{III} is

25

30

- 17 -



5

hydrogen, are preferably prepared by reacting the sulfone (Compound B Seq ID No. 31-45) with an appropriately substituted amine $R^{II}R^{III}NH$. The reaction may be carried out by adding the amine to a stirred solution of the sulfone for time sufficient for reaction to take place. The product may be recovered by purifying by preparative HPLC and lyophilizing the appropriate components.

The invention also embraces acid addition salts. The compound in the normal course of isolation is obtained as an acid addition salt. Generally, it is as a trifluoroacetic acid salt. The salt thus obtained may be dissolved in water and passed through an anion exchange column bearing the desired anion. The eluate containing the desired salt may be concentrated to recover the salt as a solid product.

The compounds of the present invention are active against many fungi and particularly against Candida species. The antifungal properties may be illustrated with the minimum fungicidal concentration (MFC) determination against certain Candida organisms in a microbroth dilution assay carried out in a Yeast Nitrogen Base (DIFCO) medium with 1% dextrose (YNBD).

In a representative assay, compounds were solubilized in 100% dimethyl sulfoxide (DMSO) at an initial concentration of 5 mg/ml. Once dissolved, the drug stock was brought to a concentration of 512 $\mu\text{g/ml}$ by dilution in water such that the final DMSO concentration was about 10 percent. The solution was then dispensed via a multichannel pipetter into the first column of a 96-well plate (each well containing 0.075 ml of YNBD), resulting in a drug concentration of 256 $\mu\text{g/ml}$. Compounds in the first column were diluted 2-fold across the rows yielding final drug concentration ranging from 256 $\mu\text{g/ml}$ to 0.12 $\mu\text{g/ml}$.

Four-hour broth cultures of organisms to be tested were adjusted using a spectrophotometer at 600 nm to equal a 0.5 McFarland

- 18 -

Standard. This suspension was diluted 1:100 in YNBD to yield a cell concentration of $1-5 \times 10^4$ colony forming units (CFU)/ml. Aliquots of the suspension (0.075 ml) were inoculated into each well of the microtiter plate resulting in a final cell inoculum of $5-25 \times 10^3$.

CFU/ml and final drug concentrations ranging from 128 µg/ml to 0.06 µg/ml. Each assay includes one row for drug-free control wells and one row for cell-free control wells.

After 24 hours of incubation, the microtiter plates were shaken gently on a shaker to resuspend the cells. The MIC-2000 inoculator was used to transfer a 1.5 microliter sample from each well of the 96-well microtiter plate to a single reservoir inoculum plate containing Sabouraud dextrose agar (SDA). The inoculated SDA plates were incubated for 24 hours at 35°C. The results were as follows:

15

20

25

30

- 19 -

COMPOUND †			ORGANISM			
R1	R2	R3	RII , RIII	<u>C. albicans</u>		C. <u>parapsilosis</u> <u>tropicalis</u>
				MY 1055	MY 1028 MY 1750	MY 1010 MY 1012
1) H	H	-CH ₂ CH ₂ NH ₂	H; CH ₂ CH ₂ NH ₂	0.250	0.125	0.125
2) H	H	-CH ₂ CONH ₂	H; CH ₂ CH ₂ NH ₂	1.000	0.500 1.000	0.500
3) H	H	-CH ₂ CH ₂ NH ₂	H; H	0.125	<0.060 0.125	0.060
4) OH	H	-CH ₂ CH ₂ NH ₂	H; CH ₂ CH ₂ NH ₂	<0.060	0.125 <0.060	<0.060

* RI = DMTD;

† as acid addition salts

- 20 -

The compounds also show in vivo effectiveness against fungi which may be demonstrated with the same compounds of the in vitro assay.

5 Growth from an overnight SDA culture of Candida albicans MY 1055 was suspended in sterile saline and the cell concentration determined by hemacytometer count and the cell suspension adjusted to 3.75×10^5 cells/ml. Then 0.2 milliliter of this suspension was administered I.V. in the tail vein of mice so that the final inoculum was 7.5×10^4 cells/mouse.

10 The assay then was carried out by administering aqueous solutions of Compound I at various concentrations intraperitoneally (I.P.), twice daily (b.i.d.) for four consecutive days to 18 to 20 gram female DBA/2 mice, which previously had been infected with Candida albicans in the manner described above. Distilled water was
15 administered I.P. to C. albicans challenged mice as controls. After seven days, the mice were sacrificed by carbon dioxide gas, paired kidneys were removed aseptically and placed in sterile polyethylene bags containing 5 milliliters of sterile saline. The kidneys were
20 homogenized in the bags, serially diluted in sterile saline and aliquots spread on the surface of SDA plates. The plates were incubated at 35°C for 48 hours and yeast colonies were enumerated for determination of colony forming units (CFU) per gram of kidneys. Compounds (1), (2), (3) and (4) gave >99 percent reduction of recoverable Candida CFUs at
25 0.09 and 0.375 mg/kg I.P. twice daily for four consecutive days.

30 The compounds of the present invention are also useful for inhibiting or alleviating Pneumocystis carini infections in immune-compromised patients. The efficacy of the compounds of the present invention for therapeutic or anti-infection purposes may be demonstrated in studies on immunosuppressed rats.

 In a representative study, the effectiveness of Compound I-6-1 ($R_1 = OH$; $R_2 = H$; $R_3 = CH_2CH_2NH_2$; $R^I = DMTD$; $R^{II} = H$; $R^{III} = CH_2CH_2NH_2$) was determined. Sprague-Dawley rats (weighing approximately 250 grams) were immunosuppressed with dexasone in the drinking water (2.0 mg/L) and maintained on a low protein diet for

- 21 -

seven weeks to induce the development of pneumocystis pneumonia from a latent infection. Before drug treatment, two rats were sacrificed to confirm the presence of Pneumocystis carinii pneumonia (PCP); both rats were found to have infections. Five rats (weighing approximately 150 grams) were injected twice daily for four days subcutaneously (sc) with Compound I-6-1 in 0.25 ml of vehicle (distilled water). A vehicle control was also carried out. All animals continued to receive dexasone in the drinking water and low protein diet during the treatment period. At the completion of the treatment, all animals were sacrificed, the lungs were removed and processed, and the extent of disease determined by microscopic analysis of stained slides. The results of this study showed Compound I-6-1 reduced P. carinii cysts in 5 rats by at least 90 percent when dosed at .075 mg/kg with all rats surviving.

The outstanding properties are most effectively utilized when the compound is formulated into novel pharmaceutical compositions with a pharmaceutically acceptable carrier according to the conventional pharmaceutical compounding techniques.

The novel compositions contain at least a therapeutic antifungal or antipneumocystis amount of the active compound. Generally, the composition contains at least 1% by weight of Compound I. Concentrate compositions suitable for dilutions prior to use may contain 90% or more by weight. The compositions include compositions suitable for oral, topical, parenteral (including intraperitoneal, subcutaneous, intramuscular, and intravenous), nasal, and suppository administration, or insufation. The compositions may be prepacked by intimately mixing Compound I with the components suitable for the medium desired.

Compositions formulated for oral administration may be a liquid composition or a solid composition. For liquid preparation, the therapeutic agent may be formulated with liquid carriers such as water, glycols, oils, alcohols, and the like, and for solid preparations such as capsules and tablets, with solid carriers such as starches, sugars, kaolin, ethyl cellulose, calcium and sodium carbonate, calcium phosphate, kaolin, talc, lactose, generally with lubricant such as calcium stearate,

- 22 -

together with binders disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage form. It is especially advantageous to formulate the compositions in unit dosage form (as hereinafter defined) for ease of administration and uniformity of dosage. Compositions in unit dosage form constitute an aspect of the present invention.

Compositions may be formulated for injection and may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles such as 0.85 percent sodium chloride or 5 percent dextrose in water and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Buffering agents as well as additives such as saline or glucose may be added to make the solutions isotonic. The compound may also be solubilized in alcohol/propylene glycol or polyethylene glycol for drip intravenous administration. These compositions also may be presented in unit dosage form in ampoules or in multidose containers, preferable with added preservative. Alternatively, the active ingredients may be in powder form for reconstituting with a suitable vehicle prior to administration.

The term "unit dosage form" as used in the specification and claims refers to physically discrete units, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the pharmaceutical carrier. Examples of such unit dosage forms are tablets, capsules, pills, powder packets, wafers, measured units in ampoules or in multidose containers and the like. A unit dosage of the present invention will generally contain from 100 to 200 milligrams of one of the compounds.

When the compound is for antifungal use any method of administration may be employed. For treating mycotic infections, oral or intravenous administration is usually employed.

When the compound is to be employed for control of pneumocystis infections it is desirable to directly treat lung and bronchi. For this reason inhalation methods are preferred. For administration by inhalation, the compounds of the present inventions are conveniently

- 23 -

delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of Compound I in suitable propellants, such as fluorocarbons or hydrocarbons.

Although the compounds of the present invention may be employed as tablets, capsules, topical compositions, insufflation powders, suppositories and the like, the solubility of the compounds of the present invention in water and aqueous media render them adaptable for use in injectible formulations and also in liquid compositions suitable for aerosol sprays.

The following examples illustrate the invention but are not to be construed as limiting.


Examples 1-3 illustrate the preparation of the products by the first method described, namely proceeding through the sulfone. This method may be employed in the preparation of any of the compounds but must be employed to obtain a useful yield of product when R_I is OH.

Examples 4 and following illustrate preparation of the products by direct substitution of nitrogen for oxygen into the hemiaminal position "5-om". This method is preferred when R_I is H, and R^{II} and R^{III} are H.

Example 3 illustrates employing as starting material, a compound in which R₃ has already been reduced to CH₂CH₂NH₂ from the natural product state where R₃ is CH₂CONH₂. Similarly for compounds in which R₃ is -CH₂CN, the already partially modified compound may be employed.

Examples 9 and 10 illustrate carrying out the conversion of the hemiaminal oxygen to nitrogen and then converting the CH₂CN or CH₂CH₂NH₂.

- 24 -

EXAMPLE 1

Part A. Preparation of Intermediate 1-[4-hydroxy-5-(epi)-aminoethylthio-N²-(10,12-dimethyl-1-oxotetradecyl)ornithine]-5-(3-hydroxyglutamine)-6-(3-hydroxyproline)echinocandin B (Seq ID No 34)

A solution of 500 mg (0.47 mmol) of pneumocandin B₀ (Seq ID No 19), 5.34g (47 mmol) of 2-amino-ethanethiol hydrochloride and 109 mg (0.47 mmol) of (1S)-(+)-10-camphorsulfonic acid in 40 ml anhydrous DMF was stirred at 25°C for 6 days. The reaction mixture was diluted with 40 ml of water and flash chromatographed on "LICHROPREP" RP18 (40-63 μm, 15.0g) packed with 10% acetonitrile/water. The column was eluted with 10 to 40% acetonitrile/water, collecting two 120 ml fractions at each 10 percent gradient. From the two 40% acetonitrile/water fractions was obtained 185 mg of material which was purified by preparative HPLC "ZORBAX" C8 (21.2 x 250mm), eluting with 40-45%

- 25 -

acetonitrile/water (0.1% TFA) to obtain 128 mg of 1-[4-hydroxy-5-(epi)-aminoethylthio-N²-(10,12-dimethyl-1-oxotetradecyl)-ornithine]-5-(3-hydroxyglutamine)-6-(3-hydroxyproline)-echinocandin B trifluoroacetate as a white amorphous solid.

¹H NMR (400 MHz, CD₃OD) δ 1.34 (d, J= 6.3 Hz, 3H), 2.89 (m, 2H), 4.72 (d, J=4.9 Hz, 1H)

FAB-MS (Li), m/e 1131 (MH+Li)⁺

Part B. Preparation of Intermediate Sulfone (Seq. ID 34)

To a stirred solution of the thio compound (444 mg, 0.358 mmol) obtained in Part A, in 15 mL of 1:1 acetonitrile/water was added "OXONE" (324 mg equivalent to 1.06 mmol of potassium hydrogen persulfate). After about 45 minutes, the solution was diluted with an equal volume of water and rapidly chromatographed using reverse-phase (C18) flash chromatography column eluting with 35-43% acetonitrile/water (0.1% TFA) in 2% step gradients. The product containing fractions were lyophilized to obtain 357 mg (86% yield) of the epi-sulfone.

¹H NMR (400MHz, CD₃OD) δ 3.48 (m, 2H), 3.55 (m, 1H), 3.71 (m, 1H), 3.91 (dd, 1H), 4.00 (m, 1H), 5.17 (dd, 1H), 6.76 (d, 2H), 7.16 (d, 2H)

Part C. Preparation of Product of Formula (1); Compound I-4 (Seq ID No 4)

To a stirred solution of 1.2 g (0.945 mmol) of epi-sulfone (prepared as described in Part B) in 20 mL of anhydrous DMF was added ethylenediamine (568 mg, 9.45 mmol). After 1 hour, HPLC analysis (RP-C18, 40% CH₃CN/H₂O (0.1% TFA)) of the reaction mixture indicated complete conversion to two polar products in a ratio of 37:63. Reverse phase (C18) flash column chromatography eluting with 10-40% acetonitrile/water (0.1% TFA) in 5 percent step gradients was followed by lyophilization of the appropriate fractions to provide 200 mg (21% yield) of the normal product as the (bis)-trifluoroacetate salt.

- 26 -

¹H NMR (400 MHz, CD₃OD) δ 1.14 (d, J=6.2 Hz, 3H), 2.72 (dd, J=15.4 and 3.8 Hz, 1H), 4.10 (m, 1H), 5.04 (dd, J=8.7 and 3.2 Hz, 1H), 5.09 (dd, J=8.5 and 4.2 Hz, 1H), 5.18 (br s, 1H), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.47 (d, J=8.6 Hz, 1H), 7.71 (d, J=10.0 Hz, 1H), 8.11 (d, J=8.7 Hz, 1H), 8.71 (d, J=8.7 Hz, 1H).

FAB-MS (Li), m/z 1113.5 (MLi)⁺


The (bis)-trifluoroacetate salt from above was dissolved in H₂O and the solution passed through a Bio-Rad AG2-X8 (C1⁻) polyprep column washing with additional water. The product-containing eluate was lyophilized to give the above compounds as the (bis)-hydrochloride salt.

Lyophilization of the fractions containing the major product provided epi-product

¹H NMR (400 MHz, CD₃OD) δ 3.02 (m, 1H), 3.14 (m, 3H), 4.16 (m, 1H), 5.10 (dd, 1H), 6.76 (d, 2H), 7.14 (d, 2H).

FAB-MS (Li), m/z 1113.9 (MLi)⁺

- 27 -

EXAMPLE 2

Part A. Preparation of Intermediate Sulfone (Seq. ID No. 36)

The starting compound, Compound A-6 $R^I = \text{DMTD}$ (Seq. ID No. 21), was prepared as described for such compound in the section entitled Preparation of Starting Materials.

Compound A-6 was then converted to the epi-thio compound Compound B-6 (Seq ID. No. 36) in a manner similar to that described in Part A of Example 1.

To a stirred solution of 285 mg (0.241 mmol) of Compound B-6 in 14 mL of 1:1 acetonitrile/water was added "OXONE" (162 mg equivalent to 0.530 mmol of potassium hydrogen persulfate). After a period of 45 minutes, the solution was diluted with an equal volume of water and chromatographed. Reverse-phase (C18) flash column chromatography eluting with 30-45% acetonitrile/water (0.1% trifluoroacetic acid) in 5% step gradients was followed by lyophilization of the product-containing fractions to provide 212 mg of the epi-sulfone (Compound C-6 Seq ID. No. 36) Yield = 84%.

- 28 -

^1H NMR (400 MHz, CD_3OD) δ 3.08 (M, 2H), 3.46 (t, $J=6.6$ Hz, 2H), 3.68 (m), 5.05 (M), 6.77 (d, $J=8.5$ Hz, 2H), 7.15 (d, $J=8.5$ Hz, 2H)
FAB-MS (Li), m/z 1039.9

5

Part B. Preparation of the Product of Formula (2)
(Compound I-6; $\text{R}^{\text{II}}=\text{H}$; $\text{R}^{\text{III}}=2\text{-aminoethyl}$); Seq ID No. 6

10

To a stirred solution of Compound C-6 (prepared as described in Part A, 418 mg, 0.305 mmol) in 10 mL of anhydrous N,N-dimethylformamide was added ethylenediamine (183 mg, 3.05 mmol). After a period of 1h, HPLC analysis (RP-C18, 35% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (0.1% CF_3COOH)) of the reaction mixture indicated complete conversion to two polar products in a ratio of 36:64. The reaction mixture was diluted with aqueous trifluoroacetic acid (190 mL H_2O , 0.4 mL CF_3COOH) and chromatographed. Reverse-phase (C18)

15

flash column chromatography eluting with 10-25% acetonitrile/water (0.1% trifluoroacetic acid) in 5% step gradients was followed by lyophilization of the appropriate fractions to provide 111 mg of the product as the (tris)-trifluoroacetate salt:

20

Yield=25%

^1H NMR (400 MHz, CD_3OD) δ 1.17 (d, $J=6.2$ Hz), 2.44 (dd, $J=7.0$ and 13.2 Hz, 1H), 2.7-3.0 (m, 4H), 3.06 (t, $J=7.0$ Hz, 2H), 3.82 (m, 3H), 3.97 (dd, $J=11.2$ and 3.2 Hz, 1H), 4.03 (m, 2H), 4.70 (d, $J=2.3$ Hz, 1H), 5.00 (d, $J=3.3$ Hz, 1H), 6.75 Hz (d, $J=8.6$ Hz, 2H), 7.11 (d, $J=8.6$ Hz, 2H)


25

FAB-MS (Li), m/z 1099.9 (MLi^+), 1033.9

30

The (tris)-trifluoroacetate salt from above was dissolved in H_2O and the solution passed through a Bio-Rad AG2-X8 (Cl^-) polyprep column washing with additional water. The product-containing eluate was lyophilized to give 93 mg of the above compound as the (tris)-hydrochloride.

- 29 -

EXAMPLE 3Part A: Preparation of Azide (Seq. ID No. 49)

To a stirred solution of 297 mg, 0.257 mmol epi-sulfone (Example 1, Part B) in 10 milliliters of anhydrous dimethylformamide was added lithium azide (126 mg, 257 mmol). After a period of 1 hr, HPLC analysis (RP-18, 40% CH₃CN/H₂O (0.1% of CF₃COOH)) of the reaction mixture indicated complete conversion to a single substantially less polar product. Reverse phase (C18) flash column chromatography eluting with 30-65% acetonitrile/water in 5% step gradients was followed by lyophilization of the product-containing fractions to provide crude azide. Preparative HPLC (C18, 40-45% CH₃CN /H₂O (0.1% CF₃COOH) in one 5% step gradient) produced an azido compound, Compound D-4, (Seq. ID No. 49).

¹H NMR (400 MHz, CD₃OD) δ 1.14 (d, J=6.1 Hz, 3H), 2.50 (dd, J=15.6 and 9.9 Hz, 1H), 2.84 (dd, J=15.6 and 3.3 Hz, 1H), 3.95 (dd, J=11.2 and 3.1 Hz, 1H), 4.05 (m, 2H), 4.56 (m, 3H), 4.98 (dd, J=8.5 and 3.5 Hz, 1H), 5.10 (dd, J=8.3 and 4.2 Hz, 1H), 5.26 (dd, J=8.5 and 2.2 Hz, 1H), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.44 (d,

- 30 -

J=8.3 Hz, 1H), 7.76 (d, J=9.9 Hz, 1H), 8.26 (d, J=8.1 Hz, 1H), 8.83 (d, J=8.7 Hz, 1H), 9.00 (d, J=8.5 Hz, 1H)

FAB-MS (Li), m/z 1096.9 (MH+Li)⁺

IR (Nujol mull, cm⁻¹) 2110

Part B: Preparation of the Amine (Seq. ID No. 4)

A mixture of azido compound D-4, prepared in Part A, (137 mg, 0.126 mmol) and 10% Pd/C (137 mg) in glacial acetic acid (10 mL) was hydrogenated under balloon pressure for a period of 14 h. The catalyst was removed by filtration and the filtrate was lyophilized to obtain the crude amine. Purification by preparative HPLC (C18, 35-41% CH₃CN/H₂O (0.1% CF₃COOH) in 3% step gradients), followed by lyophilization of the appropriate fractions provided the aza compound, Compound I-1, R^{II}, R^{III} = H (Seq. ID No. 1) as the trifluoroacetate salt: Yield = 48%


¹H NMR (400 MHz, CD₃OD) δ 1.13 (d, J=6.1 Hz, 3H), 2.49 (dd, J=15.6 and 9.8 Hz, 1H), 2.81 (dd, J=15.6 and 3.4 Hz, 1H), 3.97 (dd, J=11.1 and 3.1 Hz, 1H), 4.03 (m, 1H), 4.11 (m, 1H), 4.47 (dd, J=11.7 and 5.5 Hz, 1H), 4.57 (m, 2H), 5.00 (m, 1H), 5.10 (m, 1H), 5.14 (d, J=2.2 Hz, 1H), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.42 (d, J=8.3 Hz, 1H), 8.89 (d, J=8.8 Hz, 1H)

FAB-MS(Li), m/z 1071.0 (MLi)⁺

The trifluoroacetate was dissolved in H₂O and the solution passed through a Bio-Rad AG2-X8 (Cl⁻) polyprep column, washing with additional water. The product-containing eluate was lyophilized to obtain 66 mg of compound I-4, R^{II}, R^{III} = H (Seq ID No. 1) as the hydrochloride.

- 31 -

In the following experiments, Solvent A = 95% water/5% acetonitrile/0.1% trifluoroacetic acid and Solvent B = 95% acetonitrile/5% water/0.1% trifluoroacetic acid. When the expression "in vacuo" or "rotovaped" is used, it refers to removal of solvent on a rotary evaporator.

EXAMPLE 4

A. Preparation of Intermediate Azide Compound D-1 (Seq ID No. 46)

Pneumocandin B₀ (Compound A-4; Seq ID No. 19) (5.00 g, 4.69 mmol) was dissolved in 2M LiClO₄ - diethyl ether at room temperature. Trifluoroacetic acid (2.50 ml) was added to the stirring solution followed by triethylsilane (5.00 ml). The heterogeneous mixture was stirred rapidly for 6 hours after which time little or no starting pneumocandin B₀ was detectable by analytical HPLC (C18 "ZORBAX", 45% Solvent A/55% Solvent B/0.1% TFA, 1.5 ml/min). The mixture was poured into 200 ml of distilled water, filtered and air dried. The wet solid was stirred with diethyl ether, filtered and air

- 32 -

dried to obtain 5.6 g of crude monoreduced pneumocandin B₀.
(Compound A-1; Seq ID No. 16).

5 The crude isolate from above was added, as a solid, to a
preformed solution of HN₃ prepared by dissolving NaN₃ (3.06 g, 47.0
mmol) in 100 ml of trifluoroacetic acid with cooling. After stirring at
room temperature for 30 minutes, the reaction mixture was poured into
350 ml of distilled water and stirred for 15 minutes. The precipitate
was filtered, dissolved in methanol and the solvent removed in vacuo.
10 The residual water was removed by azeotropic removal with 100%
ethanol. The final solid was subjected to high vacuum to remove
volatiles. The mixture was purified in two equal batches by preparative
HPLC (C18 "DELTAPAK", 60 ml/min, 48 ml fractions) using a step
gradient elution from 70% A/30% B to 50% A/50% B. The
15 appropriate fractions were combined (determined by UV monitoring at
 $\lambda=220$ and 277 nm). Impure fractions were combined and reprocessed
in a similar fashion as described above. A total of 1.78 g (35% yield)
of azide D-1 (Seq ID No. 46) was obtained in this manner.
1H NMR (400 MHz, CD₃OD): δ 7.02 (d, 2H), 6.69 (d, 2H), 5.30 (d,
1H), 5.11 (d, 1H), 4.98 (d, 1H), 2.74 (dd, 1H), 1.13 (d, 3H).
20 FAB-MS (Li), m/z 1081 (MH+Li)⁺.

B. Preparation of Amine of Formula (4) Compound I-1 (R^{II},
R^{III} = H (Seq ID No. 1))

25 The purified azide compound D-1 prepared above (1.50 g)
was dissolved in 40 ml of methanol. 33% Aqueous acetic acid (15 ml)
was added followed by 0.20 g of 10% Pd-C, then the reaction vessel was
flushed with N₂. The atmosphere inside the flask was replaced with H₂
and the mixture was stirred rapidly under an atmosphere of H₂ for 3
30 hours. The suspension was filtered through a 0.2 μ m frit and the clear
solution was concentrated to dryness in vacuo. The residue was
dissolved in approximately 20 ml of distilled water, frozen and
lyophilized to obtain 1.47 g (95%) of the desired amine compound (Seq
ID No. 1) as a white solid.

- 33 -

^1H NMR (400 MHz, CD_3OD): δ 7.02 (d, 2H), 6.69 (d, 2H), 5.09 (d, 1H), 5.01 (d, 1H), 2.77 (dd, 1H), 1.15 (d, 3H).

FAB-MS (Li), m/z 1055 ($\text{MH} + \text{Li}$) $^+$


5

EXAMPLE 5

10

15

20



A. Preparation of Intermediate Benzyloxycarbonyl Compound
(Seq ID No. 1)

The amine of formula (4) from Example 4 (200 mg, 0.180 mmol) and pentafluorophenyl N-benzyloxycarbonyl-3-aminopropanoate were dissolved in 1 ml of dimethylformamide. Diisopropylethylamine (0.035 ml, 0.198 mmol) was added and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with 2 mls methanol and purified by preparative HPLC (C18 "DELTA-PAK", step gradient: 70% A/30% B to 48% A/ 52% B, 48 ml fractions). The appropriate fractions as determined by UV absorbance (220, 277 nm) were combined, frozen and lyophilized to produce 100 mg (44%) of the desired intermediate.

- 34 -

^1H NMR (400 MHz, CD_3OD): δ 7.32 (m, 5H), 7.01 (d, 2H), 6.69 (d, 2H), 5.64 (bd, 1H), 1.18 (d, 3H).
FAB-MS (Li), m/z 1259 (MLi^+)

5

B. Preparation of 3-aminopropanoyl Compound of formula (5); Compound I-1 $\text{R}^{\text{II}}=\text{H}$; $\text{R}^{\text{III}}=\text{CO}(\text{CH}_2)_2\text{NH}_2$ (Seq ID No. 1)


Benzyloxycarbonyl compound from Part A (94 mg, 0.075 mmol) was dissolved in a mixture of 3 ml methanol, 1 ml of water and 0.2 ml of acetic acid. 10% Pd-C (48 mg) was added and the vessel was flushed with N_2 gas. Next, the vessel was flushed with H_2 and the mixture was stirred vigorously under 1 atm H_2 for 2 hours. Removal of the volatiles in vacuo gave a solid. The solid was dissolved in about 4 ml of 50% aqueous acetonitrile, frozen and lyophilized to give 80 mg (91 %) of the desired compound of formula (5) as a white solid.
 ^1H NMR (400 MHz, CD_3OD): δ 7.01 (d, 2H), 6.69 (d, 2H), 6.67 (d, 1H), 5.10 (d, 1H), 4.99 (d, 1H), 3.12 (m, 2H), 1.91 (s, 3H), 1.17 (d, 3H).

FAB-MS (Li), m/z 1125 (MLi^+)

25

30

- 35 -


EXAMPLE 6

Preparation of N-Methylamino Compound of formula (6); Compound I-
1 ($R^{II}=H$; $R^{III}=CH_3$) (Seq ID No. 1)

The amine of formula (5) from Example 5 (45.6 mg, 0.135 mmol) was dissolved in 0.5 ml of dry dimethylformamide. Iodomethane (0.021 ml, 0.338 mmol) was added followed by diisopropylethylamine (0.0824 ml, 0.473 mmol). After stirring at ambient temperature for 24 hours, the volatiles were removed in vacuo and the crude product was analyzed by mass spectrometry. FAB-MS (Li), m/z 1068 (MLi)⁺

30

- 36 -

EXAMPLE 7

20 A. Preparation of Intermediate Nitrile(N-Cyanomethyl)
Compound I-1; R^{II}=H; R^{III}=CH₂CN (Seq ID No. 1)

The amine compound prepared as described in Example 4 (500 mg, 0.451 mmol) was dissolved in 3 ml of dry dimethylformamide. Bromoacetonitrile that had been prepurified by passing through a small plug of magnesium sulfate-sodium bicarbonate (0.063 ml, 0.902 mmol), was added followed by diisopropylethylamine (0.157 ml, 0.902 mmol). The clear reaction mixture was stirred for 12 hours and then diluted with a small volume of water. The solution was purified by preparative HPLC (C18 "DELTA-PAK", step gradient: 70% A/30% B to 47% A/53% B, 48 ml fractions). The appropriate fractions, as determined by UV absorbance at 220 and 277 nm, were pooled, frozen and lyophilized to yield 338 mg (62%) of the desired intermediate cyanomethyl compound as a water insoluble solid.

¹H NMR (400 MHz, CD₃OD): δ 7.01 (d, 2H), 6.69 (d, 2H), 5.12 (dd, 1H), 5.01 (dd, 1H), 3.80 (s, 2H), 2.76 (dd, 1H), 1.15 (d, 3H).

FAB-MS (Li), m/z 1094 (MH+Li)⁺

30

- 37 -


B. Preparation of N-aminoethyl Compound of formula (7);
Compound I-1; R^{II}=H; R^{III}=(CH₂)₂NH₂ (Seq ID No. 1)

The nitrile (cyanomethyl) compound prepared above (300
mg, 0.249 mmol) was dissolved in 5.0 ml of methanol. Next, nickel (II)
chloride hexahydrate (237 mg, 0.997 mmol) was added. Sodium
borohydride (189 mg, 4.99 mmol) was added to the solution in three
portions. A black precipitate formed immediately and the mixture was
stirred for 15 minutes at ambient temperature. The heterogeneous
mixture was diluted with about 20-40 ml of water and approximately
10-15 ml of 2N HCl was added. Stirring was continued for 45 minutes
until the black precipitate had dissolved and a blue-green solution
remained. Purification was accomplished by preparative HPLC (C18
"DELTAPAK", step gradient: 70% A/30% B to 55% A/45% B, 48 ml
fractions). The appropriate fractions, as determined by UV absorbance
at 220 and 277 nm, were pooled, frozen and lyophilized to yield 180 mg
(55%) of the desired product. The material was dissolved in 30 ml of
water and passed through an ion exchange column (Cl⁻ form), rinsing
with distilled water. The solution was frozen and lyophilized to obtain
149 mg (94% recovery) of the desired aminoethyl compound of
formula (7) Seq ID NO. 1 as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 7.01 (d, 2H), 6.69 (d, 2H), 5.11 (dd,
1H), 5.07 (dd, 1H), 1.14 (d, 3H).

FAB-MS (Li), m/z 1098 (MH+Li)⁺

- 38 -

EXAMPLE 8

A. Preparation of Intermediate Azide Compound (Seq ID No. 47)

20 Pneumocandin B0 nitrile (Seq ID No. 20) (2.00 g, 1.91 mmol) was dissolved in 24 ml of 2M LiClO₄ - diethyl ether. Triethylsilane (2.00 ml) followed by trifluoroacetic acid (1.00 ml) was added and the mixture was rapidly stirred at ambient temperature for 6 hours. The mixture was poured into 300 ml of water, stirred for 15

25 minutes and filtered. The filter cake was dissolved in a minimal amount of methanol and the solvent removed in vacuo. The residual water was azeotroped with 100% ethanol and the residue was subjected to high vacuum overnight to remove volatiles to obtain a product (Seq ID No. 17) mono-reduced at the benzylic carbon.

30 The crude solid from above and sodium azide (1.26 g, 19.4 mmol) were placed in a roundbottom flask equipped with a stirring bar and cooling bath. Trifluoroacetic acid (50 ml) was slowly added, the cooling bath was removed and the mixture was stirred for 2 hours. It was poured into 300 ml of water and filtered. The solid was dissolved

- 39 -

in methanol, rotovaped and pumped under high vacuum to remove volatiles. The crude material was purified by preparative HPLC (C18 "DELTA-PAK", step gradient: 55% A/45% B to 45% A/55% B, 56 ml fractions). The appropriate fractions, as determined by UV absorbance at 220 and 277 nm, were pooled, frozen and lyophilized to yield 0.59 g (29%) of the desired intermediate azide (Seq ID No. 47).

¹H NMR (400 MHz, CD₃OD): δ 7.00 (d, 2H), 6.69 (d, 2H), 5.34 (d, 1H), 5.07 (d, 1H), 5.00 (m, 1H), 2.88 (dd, 1H), 1.17 (d, 3H).

FAB-MS (Li), m/z 1036 (M-N₂+Li)⁺


B. Preparation of Compound of Formula (8) (Seq ID No. 48)

The purified azide from Part A (0.15 g, 0.142 mmol) was dissolved in a mixture of 4 ml methanol, 1 ml water and 0.5 ml of acetic acid. 10% Pd-C (50 mg) was added to the solution. The reaction flask was flushed with N₂, then with H₂. The mixture was rapidly stirred at ambient temperature for 5 hours under 1 atmosphere of H₂. Subsequent filtration through a 0.2 μm frit and removal of the volatiles in vacuo produced 0.124 g (80%) of the desired compound of formula (8) Compound I-2; R^{II}, R^{III}=H; R^I=DMTD (Seq ID No. 2) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 7.00 (d, 2H), 6.69 (d, 2H), 5.04 (d, 1H), 5.01 (m, 1H), 2.79 (dd, 1H), 1.18 (d, 3H).

FAB-MS (Li), m/z 1037 (MH+Li)⁺

- 40 -

EXAMPLE 9Preparation of Amine Compound of Formula (9) (Seq ID No. 3).

20 The purified azide-nitrile from Example 8, Part A (44 mg , 0.0416 mmol) was dissolved in 1.5 ml of methanol followed by $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ (59 mg, 0.25 mmol). Next, NaBH_4 (8 X 12 mg, 2.50 mmol) was added cautiously in portions. The black, heterogeneous reaction mixture was stirred for 30 minutes at ambient temperature. The reaction was quenched by adding about 1.5 ml of 2N HCl and enough acetic acid to dissolve the precipitate. The pale solution was


25 diluted with 3 ml of water and purified by preparative HPLC (C18 "ZORBAX", step gradient: 70% A/30% B to 60%A/40% B, 15 ml/min, 15 ml fractions). The appropriate fractions as determined by UV absorbance at 210 and 277 nm, were pooled, frozen and lyophilized to

30 obtain 38 mg (72%) of the desired compound of formula (9) as a white solid.

^1H NMR (400 MHz, CD_3OD): δ 6.99 (d, 2H), 6.70 (d, 2H), 5.11 (d, 1H), 5.0 (m, 1H), 3.05 (m, 2H), 1.17 (d, 3H).

FAB-MS (Li), m/z 1041 ($\text{MH}+\text{Li}$) $^+$

- 41 -

EXAMPLE 10

A. Preparation of Intermediate Bis-nitrile Compound
(Compound I-2; R^{II}=H; R^{III}=CH₂CN; R^I=DMTD) (Seq ID
No. 2)

The nitrile-amine compound of Example 8 Part B (500 mg, 0.459 mmol) was dissolved in 3 ml of dry dimethylformamide.

Bromoacetonitrile that had been prepurified by passing through a small plug of magnesium sulfate-sodium bicarbonate (0.064 ml, 0.917 mmol), was added followed by diisopropylethylamine (0.155 ml, 0.917 mmol).

The reaction mixture was stirred at ambient temperature for 18 hours.

It was diluted with water and purified by preparative HPLC (C18

"DELTAPAK", 60 ml/min, step gradient: 70% A/30% B to 50%

A/50% B, 48 ml fractions). The appropriate fractions, as determined

by UV absorbance at 220 and 277 nm, were pooled, frozen and

lyophilized to obtain 198 mg (36%) of the desired Compound I-2;

R^{II}=H; R^{III}=CH₂CN

¹H NMR (400 MHz, CD₃OD): δ 7.00 (d, 2H), 6.69 (d, 2H), 5.08 (dd, 1H), 5.01 (dd, 1H), 3.73 (s, 2H), 2.79 (dd, 1H), 1.18 (d, 3H).

- 42 -

FAB-MS (Li), m/z 1076 (MH+Li)⁺B. Preparation of Compound of formula (10) (Seq ID No. 3)

5 The bis-nitrile from Part A (184 mg, 0.155 mmol) was dissolved in 3 ml of methanol. NiCl₂•6H₂O (148 mg, 0.621 mmol) was dissolved in the methanol and NaBH₄ (117 mg, 3.1 mmol) was added in three portions. After 5 minutes, CoCl₂•6H₂O (148 mg, 0.621 mmol) was added and stirred about 1 minute. An additional 117 mg of NaBH₄ was added and stirring was continued for 15 minutes. Another 60 mg portion of NaBH₄ was added to drive the reaction to completion. The mixture was diluted with water, acidified with 2N HCl and stirred until the black precipitate dissolved. Purification by preparative HPLC (C18 "ZORBAX", 15 ml/min, step gradient: 70% A/30% B to 55% A/45% B, 22.5 ml fractions, 220, 277 nm) gave after lyophilization a solid. 15 The solid was dissolved in water and passed through an ion exchange column (Cl⁻ form), frozen and lyophilized to give 81.1 mg (44%) of the desired compound of formula (10) (Compound I-3 (Seq ID No. 3) as a white solid. 20 ¹H NMR (400 MHz, CD₃OD): δ 7.00 (d, 2H), 6.70 (d, 2H), 3-3.3 (m, 6H), 1.18 (d, 3H). FAB-MS (Li), m/z 1084 (MH+Li)⁺

EXAMPLE 11-14

25 In operations carried out in a manner similar to that described in Example 4, the appropriate cyclopeptide natural products or modified natural products obtained as described hereinafter on preparation of starting materials are in separate operations dissolved in LiClO₄-diethyl ether and to it is added with stirring trifluoroacetic acid and triethylsilane for 5 to 10 hours. The mixture is then poured into water, filtered, and the solid stirred with diethyl ether, then filtered and air dried to obtain cyclopeptide in which R₁ has been reduced to H. 30

The monoreduced compound is added to a preformed solution of HN₃ (from NaN₃ and trifluoroacetic acid) with cooling and

- 43 -

stirred at room temperature form 30 minutes to one hour and then poured into water to obtain the azide product which is recovered in the manner previously described.

5 The azide is hydrogenated as previously described using Pd/C as catalyst and the product is recovered from the filtrate after separation of the catalyst.

The products obtained in this manner are as follows:

10	Example	R ^I	R ²	R ³	NR ^{II}	R ^{III}	R ^I	Seq. ID No.
	11	H	H	CH ₂ CONH ₂	H	H	C ₆ H ₄ OC ₈ H ₁₇	12
	12	H	H	CH ₂ CN	H	H	C ₆ H ₄ OC ₈ H ₁₇	13
	13	H	H	CH ₂ CH ₂ NH ₂	H	H	C ₆ H ₄ OC ₈ H ₁₇	14
15	14	H	CH ₃	CH ₃	H	H	C ₆ H ₄ OC ₈ H ₁₇	15

EXAMPLES 15-17

20 In operations carried out in a manner similar to that described in Example 7, the compounds of Examples 11, 13 and 14, are dissolved in dimethylformamide and added thereto are purified bromoacetonitrile followed by diisopropylethylamine and the mixture stirred from twelve to eighteen hours to produce a nitrile (an N-cyanomethyl) compound. The latter is purified by preparative HPLC.

25 The nitrile is dissolved in methanol and reduced chemically employing nickel (II) chloride and sodium borohydride to obtain animoethyl substituted compound as follows:

30

- 44 -

	Example	R _I	R ₂	R ₃	NR ^{II}	R ^{III}	R ^I	Seq ID No.
5	15	H	H	CH ₂ CONH ₂	H	CH ₂ CH ₂ NH ₂	C ₁₀ H ₆ OC ₈ H ₁₇	12
	16	H	H	(CH ₂) ₂ NH ₂	H	CH ₂ CH ₂ NH ₂	C ₁₀ H ₆ OC ₈ H ₁₇	14
	17	H	H	CH ₃	H	CH ₂ CH ₂ NH ₂	C ₁₀ H ₆ OC ₈ H ₁₇	15

EXAMPLES 18-21

10

In operations carried out in a manner similar to that described in Example 1, 2 and 3, compounds having the substituents below may be prepared:

	Example	R _I	R ₂	R ₃	NR ^{II}	R ^{III}	R ^I	Seq ID No.
	18	OH	CH ₃	CH ₂ CONH ₂	H	CH ₂ CH ₂ NH ₂	DMTD	7
	19	OH	CH ₃	CH ₂ CH ₂ NH ₂	H	CH ₂ CH ₂ NH ₂	DMTD	8
20	20	OH	OH	CH ₂ CONH ₂	H	CH ₂ CH ₂ NH ₂	DMTD	9
	21	OH	OH	CH ₂ CH ₂ NH ₂	H	CH ₂ CH ₂ NH ₂	DMTD	14


EXAMPLES 22-25

25

In operations carried out in a manner similar to that described in Example 1, the following compounds are prepared:

	Example	R _I	R ₂	R ₃	NR ^{II}	R ^{III}	R ^I	Seq ID No.
30	22	OH	CH ₃	CH ₃	H	CH ₂ CH ₂ NH ₂	C ₆ H ₄ OC ₈ H ₁₇	10
	23	OH	CH ₃	H	H	CH ₂ CH ₂ NH ₂	C ₆ H ₄ OC ₈ H ₁₇	11
	24	OH	H	CH ₂ CH ₂ NH ₂	H	(CH ₂) ₃ NH ₂	DMTD	6
	25	OH	H	CH ₂ CH ₂ NH ₂	H	CH ₂ CH ₂ NH ₂	DMTD	6


- 45 -

EXAMPLE 26 $2\text{CF}_3\text{COOH} \cdot$ 

Seq. ID No. 6

The above compound is prepared in a manner similar to that described in Example 2, Part B, substituting dimethylamine for ethylenediamine to obtain a compound of M.W. = 1334.43.

- 46 -

EXAMPLE 27

20 The above compound is prepared in a manner similar to that in Example 26, substituting piperidine for dimethylamine to obtain a compound of M.W. 1374.

EXAMPLE 28

25 1000 compressed tablets each containing 500 mg of the compound of formula (2), [Compound I-6 ($R^{\text{II}}=H$; $R^{\text{III}}=2\text{-aminoethyl}$) Seq ID No 6.], are prepared from the following formulation:

30

<u>Compound</u>	<u>Grams</u>
Compound of Example 2	500
Starch	750
Dibasic calcium phosphate, hydrous	5000
Calcium stearate	2.5

- 47 -

The finely powdered ingredients are mixed well and granulated with 10 percent starch paste. The granulation is dried and compressed into tablets.

5

EXAMPLE 29

1000 hard gelatin capsules, each containing 500 mg of the same compound are prepared from the following formulation:

10	<u>Compound</u>	<u>Grams</u>
	Compound of Example 2	500
	Starch	250
	Lactose	750
	Talc	250
15	Calcium stearate	10

A uniform mixture of the ingredients is prepared by blending and used to fill two-piece hard gelatin capsules.

20

EXAMPLE 30

An aerosol composition may be prepared having the following formulation:

25		<u>Per Canister</u>
	Compound of Example 2	24 mg
	Lecithin NF Liquid Concd.	1.2 mg
	Trichlorofluoromethane, NF	4.026 g
30	Dichlorodifluoromethane, NF	12.15 g

- 48 -

EXAMPLE 31

250 milliliters of an injectible solution may be prepared by
conventional procedures having the following formulation:

Dextrose	12.5 g
Water	250 ml
Compound of Example 4	400 mg

The ingredients are blended and thereafter sterilized for use.

PREPARATION OF STARTING MATERIALS:

A-4 when R^I is DMTD may be produced by cultivating Zalerion arboricola ATCC 206868 in nutrient medium with mannitol as the primary source of carbon as described in U.S. Patent No. 5,021, 341, June 4, 1991.

A-7 when R^I is DMTD may be produced by cultivating Zalerion arboricola ATCC 20868 in nutrient medium as described in U.S. Patent No. 4,931,352, June 5, 1990.

A-10 when R^I is linoleyl may be produced by cultivating Aspergillus nidulans NRRL 11440 in nutrient medium as described in U.S. Patent No. 4,288,549, September 8, 1981.

A-11 when R^I is 11-methyltridecyl may be produced by cultivating Aspergillus sydowi in nutrient medium as described in J. Antibiotics XL (No. 3) p 28 (1987).

A-12 may be produced by cultivation of Zalerion arboricola ATCC 20958 in nutrient medium as described in copending application Serial No. 07/630,457, filed December 19, 1990 (Atty Docket No. 18268).

Compounds in which R₁ is H may be produced as described in Example 4, Part A.

- 49 -

Compounds in which R₃ is CH₂CN such as A-2, A-5 and A-8 may be produced by the reaction of a compound having a carboxamide group in the corresponding position with excess cyanuric chloride in an aprotic solvent. Molecular sieves may be employed in this reaction. After completion of the reaction, the sieves, if employed, are removed, and the filtrate concentrated to obtain the nitrile compound as more fully described in copending application, Ser No. 936,434, September 3, 1992.

Compounds in which R₃ is CH₂CH₂NH₂ such as A-3, A-6 and A-9 may be produced by either a chemical or catalytic reduction of the nitrile. It is conveniently carried out employing large molar excess of sodium borohydride with cobaltous chloride as more fully described in copending application Ser. No. 936,558, September 3, 1992.

Starting materials in which R^I is a different group from that of the natural product may be obtained by deacylating the lipophilic group of the natural product by subjecting the natural product in a nutrient medium to a deacylating enzyme until substantial deacylation occurs, said enzyme having first been obtained by cultivating a microorganism of the family Pseudomonadaceae or Actinoplanaceae, as described in Experientia 34, 1670 (1978) or U.S. 4,293,482, recovering the deacylated cyclopeptide, and thereafter acylating the deacylated cyclopeptide by mixing together with an appropriate active ester R^ICOX to obtain Compound A with the desired acyl group.

- 50 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANTS: BALKOVEC, JAMES M.
BLACK, REGINA M.
BOUFFARD, FRANCES AILEEN
- (ii) TITLE OF INVENTION: AZA CYCLOPEPTIDE COMPOUNDS
- (iii) NUMBER OF SEQUENCES: 60
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: ELLIOTT KORSEN
 - (B) STREET: P.O. BOX 2000, 126 EAST LINCOLN AVE.
 - (C) CITY: RAHWAY
 - (D) STATE: NEW JERSEY
 - (E) COUNTRY: USA
 - (F) ZIP: 07065
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: FLOPPY DISK
 - (B) COMPUTER: MACINTOSH CENTRIS 650
 - (C) OPERATING SYSTEM 7.1
 - (D) SOFTWARE: MICROSOFT WORD 5.1a
- (vi) CURRENT APPLICATION DATE:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA: NONE
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: ELLIOTT KORSEN
 - (B) REGISTRATION NUMBER: 32,705
 - (C) REFERENCE/DOCKET NUMBER: 18955P
- (ix) TELECOMMUNICATION INFORMATION
 - (A) TELEPHONE: 908-594-5493
 - (B) TELEFAX: 908-594-4720
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
 - (A) DESCRIPTION: PEPTIDE

- 51 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 2
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 3
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 4
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 5
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:

- 52 -

- (A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 6
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 7
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 8
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 9
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

- 53 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 10
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10
Xaa Ser Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 11
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 12
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 13
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

- 54 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- (2) INFORMATION FOR SEQ ID NO: 14
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- (2) INFORMATION FOR SEQ ID NO: 15
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- (2) INFORMATION FOR SEQ ID NO: 16
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 55 -

- (2) INFORMATION FOR SEQ ID NO: 17
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 18
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 19
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 20
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 56 -

(2) INFORMATION FOR SEQ ID NO: 21

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 22

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 23

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 24

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE

- 57 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 25
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 26
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 27
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 28
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE

- 58 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28

Xaa Thr Xaa Xaa Xaa Xaa

1

5

(2) INFORMATION FOR SEQ ID NO: 29

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6

(B) TYPE: AMINO ACID

(C) STRANDEDNESS: NA

(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29

Xaa Thr Xaa Xaa Xaa Xaa

1

5

(2) INFORMATION FOR SEQ ID NO: 30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6

(B) TYPE: AMINO ACID

(C) STRANDEDNESS: NA

(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30

Xaa Thr Xaa Xaa Xaa Xaa

1

5

(2) INFORMATION FOR SEQ ID NO: 31

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6

(B) TYPE: AMINO ACID

(C) STRANDEDNESS: NA

(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31

Xaa Thr Xaa Xaa Xaa Xaa

1

5

(2) INFORMATION FOR SEQ ID NO: 32

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6

(B) TYPE: AMINO ACID

(C) STRANDEDNESS: NA

(D) TOPOLOGY: CIRCULAR

- 59 -

- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 33
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 34
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 35
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 36
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:

- 60 -

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 38

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 39

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39

Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 61 -

- (2) INFORMATION FOR SEQ ID NO: 40
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40
- | | | | | | |
|-----|-----|-----|-----|-----|-----|
| Xaa | Ser | Xaa | Xaa | Xaa | Xaa |
| 1 | | | | | 5 |
- (2) INFORMATION FOR SEQ ID NO: 41
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41
- | | | | | | |
|-----|-----|-----|-----|-----|-----|
| Xaa | Thr | Xaa | Xaa | Xaa | Xaa |
| 1 | | | | | 5 |
- (2) INFORMATION FOR SEQ ID NO: 42
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42
- | | | | | | |
|-----|-----|-----|-----|-----|-----|
| Xaa | Thr | Xaa | Xaa | Xaa | Xaa |
| 1 | | | | | 5 |
- (2) INFORMATION FOR SEQ ID NO: 43
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
- (A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43
- | | | | | | |
|-----|-----|-----|-----|-----|-----|
| Xaa | Thr | Xaa | Xaa | Xaa | Xaa |
| 1 | | | | | 5 |

- 62 -

- (2) INFORMATION FOR SEQ ID NO: 44
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
 - (ii) MOLECULE TYPE:
 - (A) DESCRIPTION: PEPTIDE
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 45
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
 - (ii) MOLECULE TYPE:
 - (A) DESCRIPTION: PEPTIDE
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 46
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
 - (ii) MOLECULE TYPE:
 - (A) DESCRIPTION: PEPTIDE
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 47
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS: NA
 - (D) TOPOLOGY: CIRCULAR
 - (ii) MOLECULE TYPE:
 - (A) DESCRIPTION: PEPTIDE

- 63 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 48
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 49
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 50
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 51
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

- 64 -

- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 52
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 53
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 54
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 55
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

- 65 -

- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 56
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 57
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57
Xaa Thr Xaa Xaa Xaa Xaa
1 5
- (2) INFORMATION FOR SEQ ID NO: 58
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6
(B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
- (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58
Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 66 -

(2) INFORMATION FOR SEQ ID NO: 59

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS: NA
- (D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: PEPTIDE


(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60

Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 67 -

WHAT IS CLAIMED IS:

1. A compound having the formula



(I)

wherein:

R^I is H or OH;

R^{II} is H, CH₃ or OH;

R^{III} is H, CH₃, CH₂CN, CH₂CH₂NH₂ or CH₂CONH₂.

R^I is C₉-C₂₁ alkyl, C₉-C₂₁ alkenyl, C₁-C₁₀ alkoxyphenyl or C₁-C₁₀ alkoxy-naphthyl;

R^{II} is H, C₁-C₄ alkyl, C₃-C₄ alkenyl, (CH₂)₂₋₄OH, (CH₂)₂₋₄NR^{IV}R^V, CO(CH₂)₁₋₄NH₂;

R^{III} is H, C₁-C₄ alkyl, C₃-C₄ alkenyl, (CH₂)₂₋₄ OH, (CH₂)₂₋₄NR^{IV}R^V, or

- 68 -

R^{II} and R^{III} taken together are -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₂O(CH₂)₂- or -(CH₂)₂-NH-(CH₂)₂-;

5 R^{IV} is H or C₁-C₄ alkyl,
R^V is H or C₁-C₄ alkyl; and
acid addition salts thereof.

10 2. A compound according to Claim 1 wherein R₁ is OH, R₂ is H, R₃ is CH₂CONH₂, R^I is 9,11-dimethyltridecyl, R^{II} is H and R^{III} is -CH₂CH₂NH₂.

15 3. A compound according to Claim 1 wherein R₁ is OH, R₂ is H, R₃ is CH₂CH₂NH₂, R^I is 9,11-dimethyltridecyl, R^{II} is H and R^{III} is -CH₂CH₂NH₂.

20 4. A compound according to Claim 1 wherein R₁ is OH, R₂ is H, R₃ is CH₂CONH₂, R^I is 9,11-dimethyltridecyl, and R^{II} and R^{III} are H.

25 5. A compound according to Claim 1 wherein R₁ is H, R₂ is H, R₃ is CH₂CONH₂, R^I is 9,11-dimethyltridecyl, and R^{II} and R^{III} are H.

30 6. A compound according to Claim 1 wherein R₁ is H, R₂ is H, R₃ is CH₂CONH₂, R^I is 9,11-dimethyltridecyl, R^{II} is H and R₃ is COCH₂CH₂NH₂.

7. A compound according to Claim 1 wherein R₁ is H, R₂ is H, R₃ is CH₂CONH₂, R^I is 9,11-dimethyltridecyl, R^{II} is H, R^{III} is -CH₂CH₂NH₂.

8. A compound according to Claim 1 wherein R₁ is H, R₂ is H, R₃ is CH₂CH₂NH₂, R^I is 9,11-dimethyltridecyl, R^{II} and R^{III} are H.

- 69 -

9. A compound according to Claim 1 wherein R₁ is H, R₂ is H, R₃ is CH₂CH₂NH₂, R^I is 9,11-dimethyltridecyl, R^{II} is H and R^{III} is CH₂CH₂NH₂.

5

10. An antimicrobial composition comprising a compound of Claim 1 in admixture with a pharmaceutically acceptable carrier.

10

11. An antimicrobial composition comprising the compound of Claim 2 in admixture with a pharmaceutically acceptable carrier.

15

12. A method for controlling mycotic infections comprising administering to mammalian subject in need of treatment, an antimycotic amount of a compound of Claim 1.

20


13. A method for controlling pneumocystis pneumonia in immune-compromised patients comprising administering a therapeutically effective amount of a compound of Claim 1.

14. A compound having the formula:

25

30

- 70 -



INTERNATIONAL SEARCH REPORT

International application No.

PC 94/02580

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07K7/56 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	FR,A,2 365 554 (SANDOZ) 21 April 1978 see the whole document	1,10-12 1,2,4-7, 10-13
X Y	FR,A,2 340 947 (SANDOZ) 9 September 1977 see the whole document	1,10-12 1,2,4-7, 10-13
Y	EP,A,0 359 529 (MERCK & CO) 21 March 1990 see the whole document	1,2,4-7, 10-13
Y	EP,A,0 405 997 (MERCK & CO) 2 January 1991 see the whole document	1,2,4-7, 10-13

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

20 June 1994

Date of mailing of the international search report

22.07.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/02580

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claims 12, 13 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/93/02580

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2365554	21-04-78	AU-A- 2912777	05-04-79
		BE-A- 859067	28-03-78
		DE-A- 2742435	06-04-78
		JP-A- 53056684	23-05-78
		NL-A- 7710418	30-03-78
		SE-A- 7710503	29-03-78

FR-A-2340947	09-09-77	AU-A- 2222977	17-08-78
		BE-A- 851310	10-08-77
		DE-A- 2704030	18-08-77
		JP-A- 52116496	29-09-77
		NL-A- 7701295	16-08-77
		SE-A- 7701155	13-08-77

EP-A-0359529	21-03-90	JP-A- 2288837	28-11-90
		US-A- 5166135	24-11-92

EP-A-0405997	02-01-91	US-A- 5021341	04-06-91
		AU-B- 639698	05-08-93
		AU-A- 5797390	03-01-91
		CA-A- 2020062	31-12-90
		JP-A- 3163096	15-07-91
		US-A- 5194377	16-03-93
		US-A- 5202309	13-04-93

